DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: oxaliplatin
Drug: pemetrexed disodium

First Posted Date: 2007-07-19

Last Posted Date: 2012-05-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 42

Registration Number: NCT00503997

Locations: 🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States

and more 4 locations

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: lapatinib ditosylate
Drug: letrozole
Other: placebo

First Posted Date: 2007-07-11

Last Posted Date: 2012-08-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT00499681

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

and more 1 locations

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Not Applicable

Withdrawn

Conditions: Myeloproliferative Disorders
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Nausea and Vomiting
Solid Tumor

Interventions: Drug: ondansetron hydrochloride
Drug: aprepitant

First Posted Date: 2007-07-11

Last Posted Date: 2013-04-02

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT00499668

Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients

Completed

Conditions: Solid Tumor

First Posted Date: 2007-06-07

Last Posted Date: 2012-09-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 33

Registration Number: NCT00483457

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck Cancer

Completed

Conditions: Anxiety Disorder
Head and Neck Cancer
Lung Cancer

First Posted Date: 2007-06-07

Last Posted Date: 2013-03-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 100

Registration Number: NCT00483639

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States

A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2007-06-07

Last Posted Date: 2012-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 165

Registration Number: NCT00483821

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

National Registry and Blood Bank of Patients With Liver Cancer

Completed

Conditions: Liver Cancer

First Posted Date: 2007-06-05

Last Posted Date: 2013-08-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 151

Registration Number: NCT00482365

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: diffusion-weighted magnetic resonance imaging
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: magnetic resonance spectroscopic imaging

First Posted Date: 2007-05-17

Last Posted Date: 2023-11-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 209

Registration Number: NCT00474604

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: ABT-751

First Posted Date: 2007-05-10

Last Posted Date: 2012-07-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 27

Registration Number: NCT00471718

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: irinotecan hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2012-07-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00469898

Locations: 🇺🇸
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
🇺🇸
Owensboro Medical Health System, Owensboro, Kentucky, United States
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, Canada

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy